Article Details
Retrieved on: 2019-06-01 23:10:12
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>... Prime Therapeutics' Targeted Immuno-Oncology Drug Candidate Bemarituzumab; 14/05/2018 – <b>Renaissance Technologies</b> Buys New 1% Position ...</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here